A Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KX2-361 in Subjects With Advanced Malignancies That Are Refractory to Conventional Therapies
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2016
At a glance
- Drugs KX 02 (Primary)
- Indications Brain metastases; Cancer; Glioma
- Focus Adverse reactions; First in man
- Sponsors Athenex
- 16 Nov 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017.
- 16 Nov 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
- 30 Dec 2014 New source identified and integrated: ClinicalTrials.gov (NCT02326441).